Research Article

Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study

Table 1

Characteristics of patients before the introduction of olaparib (n = 69).

n (%)

Age at diagnosis (years), median (IQR)53 (48–59)
ECOG performance status at diagnosis
 053 (77)
 116 (23)
Primary tumor location
 Ovarian49 (71)
 Fallopian tube15 (22)
 Peritoneal5 (7)
Histological type
 Serous66 (96)
 Endometrial2 (3)
 Mucinous1 (1)
Gradus III65 (94)
FIGO stage at diagnosis
 I4 (6)
 II16 (23)
 III38 (55)
 IV10 (15)
 Unknown1 (1)
BRCA mutation type
 BRCA 156 (81)
 BRCA 213 (19)
 Both0 (0)
Testing for BRCA
 Tumor23 (34)
 Blood44 (65)
 Both1 (1)
Comorbidities28 (41)
Residual disease after primary surgery
 No macroscopic disease27 (39)
 Macroscopic disease33 (48)
 Unknown9 (13)
Ascites
 No35 (51)
 Yes26 (38)
 Unknown8 (12)

Data are presented as number (percentage) of patients if not stated otherwise. IQR = interquartile range. Data were missing for BRCA testing for 1 (1%) patient.